

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jul 2026

In- Vivo Bioequivalence study of Ligaglipatin tablets 5mg (ABIDI Pharmaceuticals, Iran) with brand drug (TRAJENTA® 5mg Boehringer Ingelheim, Germany) in Iranian healthy volunteers.

Protocol summary

Study aim

In- Vivo Bioequivalence study of Ligaglipatin tablets 5mg (ABIDA Pharmaceuticals, Iran) with brand drug (TRAJENTA® 5mg Boehringer Ingelheim, Germany) in Iranian healthy volunteers.

Design

Single dose, randomized, two sequences, two period crossover with a washout period.

Settings and conduct

This study is performed in Simin Baspar Teyf Gostar Company. This study will be conducted in two-way, cross-over and fasting, and on two sets of healthy volunteers. The study will be conducted in two periods of twenty-four hours. The interval between these two periods, which is called the wash-out time, is determined by the half-life of the drug plasma, which according to scientific sources should be at least 5 to 7 half-life of the drug in the case of the drug under study. The plan will take a week to clean up the drug, given the biological half-life of the drugs in the drug form. In the first round, candidates are divided into two groups, and the first group receives a test tablet and the second group receives a similar tablet. Blood samples will be taken by the volunteer by the technician immediately after taking the drug, and the preparation steps of the samples, including plasma separation and drug extraction, are performed to analyze the amount of drug on them.

Participants/Inclusion and exclusion criteria

24 participants will be selected from non-smoking, not pregnant people with no history of heart, kidney and liver disease or dis functions with both sex (male&female). The ages and BMIs of participant should be in the range of 18-60 and 18-25 respectively.

Intervention groups

Both groups received in cross-over design medication and testing at two different cross-sections and Therefore, the test results are independent of individual

differences and it will only show the difference in the formulation of the two drugs.

Main outcome variables

C_{max}, T_{max}, T_{1/2}, Ke (Elimination)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200105046010N8**

Registration date: **2020-08-31, 1399/06/10**

Registration timing: **prospective**

Last update: **2020-08-31, 1399/06/10**

Update count: **0**

Registration date

2020-08-31, 1399/06/10

Registrant information

Name

Javad Shokri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3661 4125

Email address

shokri.j@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-10-05, 1399/07/14

Expected recruitment end date

2021-05-04, 1400/02/14

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
In- Vivo Bioequivalence study of Ligaglipatin tablets 5mg (ABIDI Pharmaceuticals, Iran) with brand drug (TRAJENTA® 5mg Boehringer Ingelheim, Germany) in Iranian healthy volunteers.

Public title
Ligaglipatin tablets 5mg ABIDI Pharmaceuticals (TRAJENTA® 5mg Tab) , In- Vivo Bioequivalence in Iranian healthy volunteers.

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
General health(liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)
Exclusion criteria:
Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug

Age
From **18 years** old to **60 years** old

Gender
Both

Phase
Bioequivalence

Groups that have been masked
No information

Sample size
Target sample size: **24**

Randomization (investigator's opinion)
Randomized

Randomization description
People in different age groups are invited to cooperate through the advertisement.Then people are selected. Individuals will be randomly selected through advertisements. The number of individuals will be randomly selected and the first twelve will be selected as the first sequence and the second twelve will be selected as the second sequence.

Blinding (investigator's opinion)
Single blinded

Blinding description
Candidates are not aware of the test drug or brand name.

Placebo
Not used

Assignment
Crossover

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tabriz University of Medical Sciences Ethics Committee

Street address

No.48,Ferdows street, Ferdowsi Sq.

City

Tabriz

Province

East Azarbaijan

Postal code

5167874434

Approval date

2020-08-09, 1399/05/19

Ethics committee reference number

IR.TBZMED.REC.1399.504

Health conditions studied

1

Description of health condition studied

In this study the bioequivalence of test and brand of Ligaglipatin tablets 5mg will evaluated.

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Drug analysis in plasma or whole blood

Timepoint

After blood sampling

Method of measurement

HPLC,LC-MS/MS or UPLC-MS/MS

Secondary outcomes

1

Description

Pharmacokinetic parameters

Timepoint

Immediately after the intervention

Method of measurement

Theoretically and using pharmacokinetic equations

Intervention groups

1

Description

Intervention group: Single dose of 5 mg Linagliptine tablets (TRAJENTA® 5mg Boehringer Ingelheim, Germany) Pharmaceutical Company as a reference

product.
Category
Treatment - Drugs

2

Description
Intervention group 2:Single dose of 5 mg Linagliptine tablet by Abidi Pharmaceutical Company as a test product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Simin Baspar Teyf Gostar Company
Full name of responsible person
Javad Shokri
Street address
No.48,Ferdos Street
City
Tabriz
Province
East Azarbaijan
Postal code
5167874434
Phone
+98 41 3384 2724
Email
Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Amir Razavian
Street address
8 km of Shahid Lashkari highway, Karaj special road.
Obaidi Boulevard No. 72
City
Tehran
Province
Tehran
Postal code
1389776363
Phone
+98 21 4452 2451
Email
info@abidi-diabetes.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No

Title of funding source
Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences.
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
Shokri.j@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences.
City
Tabriz
Province
East Azarbaijan

Postal code
5166414766
Phone
+98 41 3334 8489
Email
Shokri.j@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences.
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
Shokri.j@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

These data are as secure between researcher and related industries.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only protocol and methods of study are sharable.

When the data will become available and for how long

After finishing of the protocol (Probably 6 months receiving IRCT code)

To whom data/document is available

Pharmaceutical and medical sciences researchers.

Under which criteria data/document could be used

Projects information's for any publications is not allowed.

From where data/document is obtainable

Contact with E-mail of the main researcher.

What processes are involved for a request to access data/document

Personal and academic details and the aim of the request.

Comments